Dendreon (NASDAQ:DNDN) has posted its results. The actual EPS and revenues don’t matter because of the stage of the company. But the company did lower its total expenses to $23.4 million. That compares to $26.3 million from Q2 2006 and roughly $28 million last quarter. Those expenses included options costs of $1.3 million and $2.9 million, respectively.
So the company slowed its cash burn rate, and that is what we wanted to see. Unfortunately the company made no new developments in the "highlights" or "disclosures." Unless the company announces some unexpected FDA developments or unless it announces a surprise partner, this one sounds like there could be a continued news vacuum.
Jon C. Ogg
August 7, 2007
Jon Ogg can be reached at [email protected]; he does not own securities in the companies he covers.
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
